Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue
Loading...
Download
Associated Records
Authors
File Licence
Editors
Date
2011-09-01
Source Title
PLoS Neglected Tropical Diseases
Journal Title
Journal ISSN
Volume Title
Publisher
PUBLIC LIBRARY SCIENCE
Melbourne Authors
Affiliation
Microbiology & Immunology
Document Type
Journal Article
Subject Code
Citation
Tricou, V., Minh, N. N., Farrar, J., Tran, H. T. & Simmons, C. P. (2011). Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. Plos Neglected Tropical Diseases, 5 (9), https://doi.org/10.1371/journal.pntd.0001309.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
BACKGROUND: Dengue is a major public health problem in tropical and subtropical countries. Exploring the relationships between virological features of infection with patient immune status and outcome may help to identify predictors of disease severity and enable rational therapeutic strategies. METHODS: Clinical features, antibody responses and virological markers were characterized in Vietnamese adults participating in a randomised controlled treatment trial of chloroquine. RESULTS: Of the 248 patients with laboratory-confirmed dengue and defined serological and clinical classifications 29 (11.7%) had primary DF, 150 (60.5%) had secondary DF, 4 (1.6%) had primary DHF and 65 (26.2%) had secondary DHF. DENV-1 was the commonest serotype (57.3%), then DENV-2 (20.6%), DENV-3 (15.7%) and DENV-4 (2.8%). DHF was associated with secondary infection (Odds ratio = 3.13, 95% CI 1.04-12.75). DENV-1 infections resulted in significantly higher viremia levels than DENV-2 infections. Early viremia levels were higher in DENV-1 patients with DHF than with DF, even if the peak viremia level was often not observed because it occurred prior to enrolment. Peak viremias were significantly less often observed during secondary infections than primary for all disease severity grades (P = 0.001). The clearance of DENV viremia and NS1 antigenemia occurs earlier and faster in patients with secondary dengue (P<0.0001). The maximum daily rate of viremia clearance was significantly higher in patients with secondary infections than primary (P<0.00001). CONCLUSIONS: Collectively, our findings suggest that the early magnitude of viremia is positively associated with disease severity. The clearance of DENV is associated with immune status, and there are serotype dependent differences in infection kinetics. These findings are relevant for the rational design of randomized controlled trials of therapeutic interventions, especially antivirals.